Atomwise unveils Chagas disease compounds from AIMS program

Atomwise has revealed the first hit identifications by two of its AIMS program collaborators, including compounds against an unexploited target for Chagas disease, for which there are few therapies.

Read the full 291 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE